Literature DB >> 25528587

Cardiac myostatin upregulation occurs immediately after myocardial ischemia and is involved in skeletal muscle activation of atrophy.

Estibaliz Castillero1, Hirokazu Akashi2, Catherine Wang1, Marc Najjar1, Ruiping Ji3, Peter J Kennel3, H Lee Sweeney4, Paul C Schulze3, Isaac George5.   

Abstract

UNLABELLED: Myostatin (MSTN), a negative regulator of muscle growth and size, is increased after acute myocardial infarction (AMI) but timing of upregulation after injury is not known. In this study, we investigated the timing of the MSTN/AKT/p38 pathway activation in heart and skeletal muscle after AMI, as well as the potential effect of cardiac injury-related MSTN endocrine signaling on skeletal muscle and other circulating growth factors.
METHODS: Coronary artery ligation was performed in C57BL/6 mice at age 8 weeks to induce AMI. Mice were sacrificed at different time points (10 m, 1 h, 2 h, 6 h, 12 h, 24 h, 1 week, 2 weeks, 1 months and 2 months) after surgery (n=3 per time point, n=18 total).
RESULTS: Cardiac and circulating MSTN upregulation occurred as early as 10 min after AMI. Two months after AMI, increased cardiac MSTN/SMAD2,3 and p38 together with decreased IGF-1/AKT signaling suggest an anti-hypertrophic profile. In skeletal muscle, an absence of local MSTN increase was accompanied by increased MSTN-dependent SMAD2,3 signaling, suggestive of paracrine effects due to cardiac-derived MSTN. Protein degradation by the ubiquitin-proteasome system in the skeletal muscle was also evident. Serum from 24h post-MI mice effectively induced a MSTN-dependent increase in atrogin1 and MuRF1.
CONCLUSION: Our study shows that cardiac MTSN activation occurs rapidly after cardiac ischemia and may be involved in peripheral protein degradation in the skeletal muscle by activating atrogin1 and MuRF1.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cardiac cachexia; Grow factors; Heart failure; Ischemia; Myostatin

Mesh:

Substances:

Year:  2014        PMID: 25528587      PMCID: PMC4967536          DOI: 10.1016/j.bbrc.2014.12.057

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  25 in total

1.  Changes in myostatin signaling in non-weight-losing cancer patients.

Authors:  Zaira Aversa; Andrea Bonetto; Fabio Penna; Paola Costelli; Gaetano Di Rienzo; Angelo Lacitignola; Francesco M Baccino; Vincenzo Ziparo; Paolo Mercantini; Filippo Rossi Fanelli; Maurizio Muscaritoli
Journal:  Ann Surg Oncol       Date:  2011-04-26       Impact factor: 5.344

2.  Myostatin activation in patients with advanced heart failure and after mechanical unloading.

Authors:  Isaac George; Lawrence T Bish; Gayathri Kamalakkannan; Christopher M Petrilli; Mehmet C Oz; Yoshifumi Naka; H Lee Sweeney; Simon Maybaum
Journal:  Eur J Heart Fail       Date:  2010-03-27       Impact factor: 15.534

3.  Sepsis downregulates myostatin mRNA levels without altering myostatin protein levels in skeletal muscle.

Authors:  Ira J Smith; Zaira Aversa; Nima Alamdari; Victoria Petkova; Per-Olof Hasselgren
Journal:  J Cell Biochem       Date:  2010-11-01       Impact factor: 4.429

4.  Wasting as independent risk factor for mortality in chronic heart failure.

Authors:  S D Anker; P Ponikowski; S Varney; T P Chua; A L Clark; K M Webb-Peploe; D Harrington; W J Kox; P A Poole-Wilson; A J Coats
Journal:  Lancet       Date:  1997-04-12       Impact factor: 79.321

5.  The aging myostatin null phenotype: reduced adiposity, cardiac hypertrophy, enhanced cardiac stress response, and sexual dimorphism.

Authors:  Melissa F Jackson; Dung Luong; Dor Dor Vang; Dilip K Garikipati; James B Stanton; O Lynne Nelson; Buel D Rodgers
Journal:  J Endocrinol       Date:  2012-03-19       Impact factor: 4.286

6.  Myostatin regulates energy homeostasis in the heart and prevents heart failure.

Authors:  Nadine Biesemann; Luca Mendler; Astrid Wietelmann; Sven Hermann; Michael Schäfers; Marcus Krüger; Thomas Boettger; Thilo Borchardt; Thomas Braun
Journal:  Circ Res       Date:  2014-05-07       Impact factor: 17.367

7.  Myostatin and follistatin expression in skeletal muscles of rats with chronic heart failure.

Authors:  Aline Regina Ruiz Lima; Paula Felippe Martinez; Katashi Okoshi; Daniele Mendes Guizoni; Leonardo A Mamede Zornoff; Dijon Henrique Salomé Campos; Sílvio Assis Oliveira; Camila Bonomo; Maeli Dal Pai-Silva; Marina Politi Okoshi
Journal:  Int J Exp Pathol       Date:  2009-12-03       Impact factor: 1.925

8.  Genetic deletion of myostatin from the heart prevents skeletal muscle atrophy in heart failure.

Authors:  Joerg Heineke; Mannix Auger-Messier; Jian Xu; Michelle Sargent; Allen York; Stephen Welle; Jeffery D Molkentin
Journal:  Circulation       Date:  2010-01-11       Impact factor: 29.690

9.  Growth differentiation factor 11 is a circulating factor that reverses age-related cardiac hypertrophy.

Authors:  Francesco S Loffredo; Matthew L Steinhauser; Steven M Jay; Joseph Gannon; James R Pancoast; Pratyusha Yalamanchi; Manisha Sinha; Claudia Dall'Osso; Danika Khong; Jennifer L Shadrach; Christine M Miller; Britta S Singer; Alex Stewart; Nikolaos Psychogios; Robert E Gerszten; Adam J Hartigan; Mi-Jeong Kim; Thomas Serwold; Amy J Wagers; Richard T Lee
Journal:  Cell       Date:  2013-05-09       Impact factor: 41.582

10.  Elevated expression of activins promotes muscle wasting and cachexia.

Authors:  Justin L Chen; Kelly L Walton; Catherine E Winbanks; Kate T Murphy; Rachel E Thomson; Yogeshwar Makanji; Hongwei Qian; Gordon S Lynch; Craig A Harrison; Paul Gregorevic
Journal:  FASEB J       Date:  2013-12-30       Impact factor: 5.191

View more
  22 in total

Review 1.  Molecular tissue changes in early myocardial ischemia: from pathophysiology to the identification of new diagnostic markers.

Authors:  Aleksandra Aljakna; Tony Fracasso; Sara Sabatasso
Journal:  Int J Legal Med       Date:  2018-01-23       Impact factor: 2.686

2.  Steps toward therapeutically targeting the activin type II receptor for treating heart failure.

Authors:  Samantha J Paddock; Caitlin C O'Meara
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-01-10       Impact factor: 4.733

Review 3.  Publication trends in cachexia and sarcopenia in elderly heart failure patients.

Authors:  Jochen Springer; Stefan D Anker
Journal:  Wien Klin Wochenschr       Date:  2016-11-24       Impact factor: 1.704

Review 4.  Myostatin: a multifunctional role in human female reproduction and fertility - a short review.

Authors:  Sijia Wang; Lanlan Fang; Luping Cong; Jacqueline Pui Wah Chung; Tin Chiu Li; David Yiu Leung Chan
Journal:  Reprod Biol Endocrinol       Date:  2022-07-02       Impact factor: 4.982

Review 5.  New insights about the putative role of myokines in the context of cardiac rehabilitation and secondary cardiovascular prevention.

Authors:  Domenico Di Raimondo; Giuseppe Miceli; Gaia Musiari; Antonino Tuttolomondo; Antonio Pinto
Journal:  Ann Transl Med       Date:  2017-08

Review 6.  Biochemistry and Biology of GDF11 and Myostatin: Similarities, Differences, and Questions for Future Investigation.

Authors:  Ryan G Walker; Tommaso Poggioli; Lida Katsimpardi; Sean M Buchanan; Juhyun Oh; Sam Wattrus; Bettina Heidecker; Yick W Fong; Lee L Rubin; Peter Ganz; Thomas B Thompson; Amy J Wagers; Richard T Lee
Journal:  Circ Res       Date:  2016-04-01       Impact factor: 17.367

7.  Activin type II receptor ligand signaling inhibition after experimental ischemic heart failure attenuates cardiac remodeling and prevents fibrosis.

Authors:  Estibaliz Castillero; Hirokazu Akashi; Marc Najjar; Ruiping Ji; Lea Maria Brandstetter; Catherine Wang; Xianghai Liao; Xiaokan Zhang; Alexandra Sperry; Marcia Gailes; Karina Guaman; Adam Recht; Ira Schlosberg; H Lee Sweeney; Ziad A Ali; Shunichi Homma; Paolo C Colombo; Giovanni Ferrari; P Christian Schulze; Isaac George
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-12-30       Impact factor: 4.733

8.  Deficiency of myostatin protects skeletal muscle cells from ischemia reperfusion injury.

Authors:  Christoph Wallner; Marius Drysch; Mustafa Becerikli; Sonja Verena Schmidt; Stephan Hahn; Johannes Maximilian Wagner; Felix Reinkemeier; Mehran Dadras; Alexander Sogorski; Maxi von Glinski; Marcus Lehnhardt; Björn Behr
Journal:  Sci Rep       Date:  2021-06-15       Impact factor: 4.379

9.  Identification of neutrophil-derived proteases and angiotensin II as biomarkers of cancer cachexia.

Authors:  Claudia A Penafuerte; Bruno Gagnon; Jacinthe Sirois; Jessica Murphy; Neil MacDonald; Michel L Tremblay
Journal:  Br J Cancer       Date:  2016-03-08       Impact factor: 7.640

10.  Paracrine and endocrine modes of myostatin action.

Authors:  Yun-Sil Lee; Thanh V Huynh; Se-Jin Lee
Journal:  J Appl Physiol (1985)       Date:  2016-01-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.